Results 131 to 140 of about 27,357 (215)
Treatment and timing in invasive mould disease [PDF]
, 2017 Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use mould-active antifungal agents is much debated. Current approaches to antifungal prophylaxis, early treatment (empirical and pre-emptive therapy) and ...
Cordonnier, Catherine +5 more
core
Infection and Drug Resistance, 2015 Ahmet SoysalDivision of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Marmara University, Istanbul, TurkeyAbstract: Posaconazole is a triazole antifungal agent that has broad-spectrum activity against many yeasts and ...
Soysal A
doaj
Farmacología de los azoles [PDF]
, 2007 Azole antifungals have different pharmacokinetic characteristics: complete oral absorption for Voriconazole, and to a lesser extent for fluconazole. The absorption of posaconazole and itraconazole increases with food intake.
Azanza, J.R. (José Ramón) +2 more
core
Posaconazole as rescue therapy in African histoplasmosis
Brazilian Journal of Infectious DiseasesPosaconazole Histoplasmosis Salvage therapy African histoplasmosis is a granulomatous mycosis caused by Histoplasma capsulatum var. duboisii. Treatment is usually extrapolated from guidelines for classical histoplasmosis, and includes 2-4 weeks of ...
Daniel Gonçalves +2 more
doaj +1 more source
Scientific ReportsPosaconazole enteric-coated tablet and oral suspension are two oral drugs in the treatment of invasive fungal infections (IFIs). This study compared the effectiveness and safety between posaconazole enteric-coated tablet and oral suspension, and provided
Yi-Lei Yang +4 more
doaj +1 more source
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
New England Journal of Medicine, 2007 O. Cornely +13 more
semanticscholar +1 more source
Therapeutic drug monitoring of voriconazole : validation of a novel ARK™ immunoassay and comparison with ultra-high performance liquid chromatography [PDF]
, 2015 Cattoir, Lien +5 more
core +1 more source
Posaconazole as rescue therapy in African histoplasmosis
Brazilian Journal of Infectious Diseases, 2013 Posaconazole Histoplasmosis Salvage therapy African histoplasmosis is a granulomatous mycosis caused by Histoplasma capsulatum var. duboisii. Treatment is usually extrapolated from guidelines for classical histoplasmosis, and includes 2-4 weeks of ...
Daniel Gonçalves +2 more
doaj
(1-3)-β-d-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations [PDF]
, 2018 Della Pepa, R. +11 more
core +1 more source
Posaconazole in the management of refractory invasive fungal infections
Therapeutics and Clinical Risk Management, 2008 Stefan Langner, Philipp B Staber, Peter NeumeisterDivision of Hematology, Department of Internal Medicine, Medical University of Graz, AustriaAbstract: The rising incidence of invasive fungal infections due to the expanding population of ...
Stefan Langner +2 more
doaj